ArticleCancers2026
Performance of PRAME Immunohistochemistry in Distinguishing Classic Hodgkin Lymphoma from Anaplastic Large Cell Lymphoma and T-Cell Lymphoma.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
BACKGROUND/
objectivesThe differential diagnosis of classic Hodgkin lymphoma (CHL) versus anaplastic large cell lymphoma (ALCL) and other T-cell lymphomas (TCL) with Hodgkin-like features remains challenging in some cases, and may require TCR molecular testing with prolonged turnaround time. The limited literature has previously described PRAME (Preferentially Expressed Antigen in Melanoma) overexpression in Hodgkin cells and its absence in cutaneous T-cell lymphomas. The aim of this study was to examine the staining pattern of PRAME in CHL compared to the pattern in non-cutaneous ALCL and TCL.
methodsTwenty-four cases of CHL, 21 cases of ALK-negative ALCL, nine cases of ALK-positive ALCL and 11 cases of other TCL were stained for PRAME.
resultsPRAME showed strong and diffuse (3+) expression in 80% of CHL cases while, in contrast, 0% of ALK-negative ALCL showed 3+ staining and 11% of ALK-positive ALCL showed 3+ staining. Non-ALCL TCL showed only 0 or 1+ staining.
conclusionsPRAME may be another helpful stain in the workup of CHL and its morphologic mimics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.